Opus Genetics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
George Magrath
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 3.0% |
| CEO tenure | less than a year |
| CEO ownership | 0.6% |
| Management average tenure | less than a year |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher
Aug 19
Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump
Jul 24Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth
Jul 12Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch
May 02Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Mar 15Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically
May 20Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%
Apr 02We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jan 27We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully
Oct 08Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment
Sep 08Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08
Aug 12Ocuphire extends IP rights for lead candidate with new U.S. patent
Aug 03Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics
Jun 29We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jun 24Is Ocuphire Pharma (NASDAQ:OCUP) In A Good Position To Invest In Growth?
Mar 22Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
Oct 08Ocuphire Pharma: An Undervalued Ophthalmic Play
Aug 05Ocuphire Pharma inks licensing deal for RX-3117 with Processa Pharma
Jun 17Ocuphire Pharma (NASDAQ:OCUP) Is In A Good Position To Deliver On Growth Plans
Jun 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$27m |
| Jun 30 2024 | n/a | n/a | -US$14m |
| Mar 31 2024 | n/a | n/a | -US$11m |
| Dec 31 2023 | US$3m | US$96k | -US$10m |
Compensation vs Market: George's total compensation ($USD3.15M) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: Insufficient data to compare George's compensation with company performance.
CEO
George Magrath (40 yo)
less than a year
Tenure
US$3,146,518
Compensation
Mr. George Magrath, MD, MBA, Ms. serves as CEO & Director of Opus Genetics, Inc. (formerly known as Ocuphire Pharma, Inc.) since November 1, 2023. He was an Analyst at Edison Investment Research Limited si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$3.15m | 0.61% $ 190.7k | |
| Senior Vice President of Corporate Development & Secretary | no data | US$789.92k | 0.34% $ 106.5k | |
| Chief Medical Advisor & Director | no data | US$662.10k | 0.23% $ 71.5k | |
| Senior Vice President of Finance | no data | US$789.92k | 0.025% $ 7.6k | |
| Chief Financial Officer | less than a year | no data | 0.48% $ 148.2k | |
| Chief Operating Officer | less than a year | no data | 0.0064% $ 2.0k | |
| Chief Scientific & Development Officer | less than a year | no data | 0.25% $ 77.6k | |
| Head of Market Development & Commercialization | 2.8yrs | no data | no data | |
| Director & Corporate Controller | no data | no data | no data |
1.0yrs
Average Tenure
46yo
Average Age
Experienced Management: IRD's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$3.15m | 0.61% $ 190.7k | |
| Chief Medical Advisor & Director | 3.4yrs | US$662.10k | 0.23% $ 71.5k | |
| Independent Director | 4yrs | US$154.81k | 0.29% $ 89.8k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 4yrs | US$1.35m | 0.52% $ 161.1k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | 4.8yrs | no data | no data | |
| Independent Director | 4yrs | US$135.34k | 0.31% $ 97.7k | |
| Independent Chairman | 4yrs | US$174.62k | 0.11% $ 35.5k | |
| Lead Independent Director | 4yrs | US$149.56k | 0.15% $ 46.7k | |
| Member of Medical Advisory Board | 2.9yrs | no data | no data | |
| Member of Medical Advisory Board | 2.9yrs | no data | no data |
4.0yrs
Average Tenure
58yo
Average Age
Experienced Board: IRD's board of directors are considered experienced (4 years average tenure).